Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Overview of attention for article published in Frontiers in oncology, June 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter: 3 X users

Readers on

mendeley: 2 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 6,872 followers.

RRIDs were included in the Frontiers in Oncology paper "Tocilizumab (monoclonal anti-IL-6R antibody) rever…" (https://t.co/r7Ket7Pc6k). We appreciate the author's support of reproducibility. #ReproducibleResearch #STMpublishing

07 Jul 2023

Reply Repost Favourite

3-23-2023: Beijing, China: After the Chinese chemotherapy drug, FOCUS V (anlotinib), had failed, the all-purpose antioxidant, Actemra (tocilizumab), was called in to rescue mice from metastatic osteosarcoma (bone-origin cancer): https://t.co/AWzXwaEnVz h

06 Jul 2023

Reply Repost Favourite

New research: Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma: Purpose Anlotinib, a tyrosine kinase inhibitor (TKI) has been in clinical application to inhibit malignant cell growth and lung… #oncology https://t.

27 Jun 2023

Reply Repost Favourite

6-19-2023: Beijing, China: The anti-cancer drug, Actemra, is praised mostly only for inhibiting the horrific side effects of cancer therapies (CAR-T, ICI, BiTE, TIL, chemotherapy, radiotherapy). Actemra enhances the efficacy of chemo drugs in many ways:

20 Jun 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.